Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy
Overall survival · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher overall survival compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
- Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes onlyHR 1.24 [1.05, 1.48]6 studies · 2712 participantsModerate